february 2002

Among the more practical advice that can be offered to international travelers is wisdom of the bathroom. So let me say, as someone who recently returned from China, that you should be prepared to (1) carry your own toilet paper and (2) practice your squat.

I do not mean those goofy chair-less sits you see at the gym. No, toned glutes will not save you here. I mean the deep squat, where you plop your butt down as far as it can go while staying aloft and balanced on the heels. This position—in contrast to deep squatting on your toes as most Americans naturally attempt instead—is so stable that people in China can hold it for minutes and perhaps even hours …

… while eating.

… while smoking.

Carl Schoonover and Andrew Fink are confused. As neuroscientists, they know that the brain must be flexible but not too flexible. It must rewire itself in the face of new experiences, but must also consistently represent the features of the external world. How? The relatively simple explanation found in neuroscience textbooks is that specific groups of neurons reliably fire when their owner smells a rose, sees a sunset, or hears a bell. These representations—these patterns of neural firing—presumably stay the same from one moment to the next. But as Schoonover, Fink, and others have found, they sometimes don’t. They change—and to a confusing and unexpected extent.

Schoonover, Fink, and their colleagues from Columbia University allowed mice to sniff the same odors over several days and weeks, and recorded the activity of neurons in the rodents’ piriform cortex—a brain region involved in identifying smells. At a given moment, each odor caused a distinctive group of neurons in this region to fire. But as time went on, the makeup of these groups slowly changed. Some neurons stopped responding to the smells; others started. After a month, each group was almost completely different. Put it this way: The neurons that represented the smell of an apple in May and those that represented the same smell in June were as different from each other as those that represent the smells of apples and grass at any one time.

Nations, like individuals, tell stories in order to understand what they are, where they come from, and what they want to be. National narratives, like personal ones, are prone to sentimentality, grievance, pride, shame, self-blindness. There is never just one—they compete and constantly change. The most durable narratives are not the ones that stand up best to fact-checking. They’re the ones that address our deepest needs and desires. Americans know by now that democracy depends on a baseline of shared reality—when facts become fungible, we’re lost. But just as no one can live a happy and productive life in nonstop self-criticism, nations require more than facts—they need stories that convey a moral identity. The long gaze in the mirror has to end in self-respect or it will swallow us up.

To survive in the frigid ocean waters around the Arctic and Antarctica, marine life evolved many defenses against the lethal cold. One common adaptation is the ability to make antifreezing proteins (AFPs) that prevent ice crystals from growing in blood, tissues, and cells. It’s a solution that has evolved repeatedly and independently, not just in fish but in plants, fungi, and bacteria.

It isn’t surprising, then, that herrings and smelts, two groups of fish that commonly roam the northernmost reaches of the Atlantic and Pacific Oceans, both make AFPs. But it is very surprising, even weird, that both fish do so with the same AFP gene—particularly because their ancestors diverged more than 250 million years ago and the gene is absent from all the other fish species related to them.

Earlier this week, the Food and Drug Administration overruled—to much criticism—its own scientific advisory committee and approved the Alzheimer’s treatment Aduhelm. The agency made this decision despite thin evidence of the drug’s clinical efficacy and despite its serious side effects, including brain swelling and bleeding. As a result, a serious risk now exists that millions of people will be prescribed a drug that does more harm than good.

Less appreciated is how the drug’s approval could trigger hundreds of billions of dollars of new government spending, all without a vote in Congress or indeed any public debate over the drug’s value. Aduhelm’s manufacturer, Biogen, announced on Monday that it would price the drug at an average of $56,000 a year per patient, a figure that doesn’t include the additional imaging and scans needed to diagnose patients or to monitor them for serious side effects.